Clinical Trials Browser

UNKNOWN × pembrolizumab × Clear all

NCT04740996 2022-02-07

Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04999800 2021-08-11

Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1

Phase 2 Unknown

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms